Live moderated video webcast with Management
to discuss potentially pivotal global study of lead asset,
Berubicin, on Wednesday, September
28th at 1:00 PM
ET
HOUSTON, Sept. 23,
2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc.
(NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical
company specializing in the development of novel treatments for
primary and metastatic cancers in the brain and central nervous
system, today announced that John
Climaco, Chief Executive Officer of CNS Pharmaceuticals,
will present at the Virtual Investor Innovations in Oncology –
Ongoing Pivotal Global Study for Treatment of Glioblastoma
Multiforme (GBM) Event on Wednesday,
September 28, 2022 at 1:00 PM
ET.
![(PRNewsfoto/CNS Pharmaceuticals, Inc.) (PRNewsfoto/CNS Pharmaceuticals, Inc.)](https://mma.prnewswire.com/media/1120277/CNS_Pharmaceuticals_Logo.jpg)
As part of the virtual event, the Company will discuss its
ongoing potentially pivotal global study evaluating its efficacy
and safety in the treatment of GBM. The potentially pivotal trial
is an adaptive, multicenter, open-label, randomized and controlled
study in adult patients with recurrent glioblastoma multiforme (WHO
Grade IV1) after failure of standard first-line therapy. The
primary endpoint of the study is Overall Survival (OS), which is a
rigorous endpoint that the FDA has recognized as a basis for
approval of oncology drugs when a statistically significant
improvement can be shown relative to a randomized control arm. The
recently amended protocol expands eligibility for the study to
patients who have received additional treatments as part of the
first line therapy for their disease considering advancements in
this area. This change was made due to the complexity of new agents
introduced as a component of first line therapy, which allows an
additional group of patients that can enroll on the study after
what may constitute multiple procedures as their initial
treatment.
A pre-planned, non-binding futility analysis will be performed
after approximately 30 to 50% of all planned patients have
completed the primary endpoint at 6 months. This review will
include additional evaluation of safety as well as secondary
efficacy endpoints. Enrollment will not be paused during this
interim analysis.
In addition to the moderated portion of the event, investors and
interested parties will have the opportunity to submit questions.
The Company will answer as many questions as possible during the
event.
A live video webcast of the Virtual Investor Innovations in
Oncology – Ongoing Pivotal Global Study for Treatment of
Glioblastoma Multiforme (GBM) Event will be available on the Events
page in the Investors section of the Company's website
(www.cnspharma.com). A webcast replay will be available two hours
following the live presentation and will be accessible for 90
days.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals a clinical-stage pharmaceutical company
developing a pipeline of anti-cancer drug candidates for the
treatment of primary and metastatic cancers of the brain and
central nervous system. The Company's lead drug candidate,
Berubicin, is a novel anthracycline and the first anthracycline to
appear to cross the blood-brain barrier. Berubicin is currently in
development for the treatment of a number of serious brain and CNS
oncology indications including glioblastoma multiforme (GBM), an
aggressive and incurable form of brain cancer.
Additionally, the Company is advancing the development of
its WP1244 drug technology portfolio, which utilizes anthracycline
and distamycin-based scaffolds to create small molecule agents and
is believed to be 500x more potent than daunorubicin in inhibiting
tumor cell proliferation. Preclinical studies of WP1244
demonstrated high uptake in the brain with antitumor activity. CNS
Pharmaceuticals is evaluating the use of the WP1244 portfolio in
the treatment of brain cancers, pancreatic, ovarian, and
lymphomas.
For more information, please visit www.CNSPharma.com, and
connect with the Company on Twitter, Facebook, and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-present-at-the-virtual-investor-innovations-in-oncology--ongoing-pivotal-global-study-for-treatment-of-glioblastoma-multiforme-gbm-301631776.html
SOURCE CNS Pharmaceuticals, Inc.